GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Drugs Made In America Acquisition DMAA · USD

N/A · US listing · 🇺🇸 United States

Compare

10.89

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Drugs Made In America Acquisition

From its filings with the US Securities and Exchange Commission

SEC filings

Drugs Made In America Acquisition is based in New York, New York. Its shares trade on Nasdaq under the ticker DMAA. The SEC classifies its business as blank checks. In the fiscal year to 31 December 2025, it reported net income of $5.9m. At that date it held total assets of $239.9m and shareholders' equity of −$7.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
28 Jan 2025
Employees
2
Head office
420 LEXINGTON AVENUE, NEW YORK, NY, 10170
Classification
Blank Checks
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Ms. Lynn StockwellExecutive Chairman of the Board, Chief Executive Officer, since 2024
  • Mr. Glenn WormanChief Financial Officer
  • Dr. Catherine DoIndependent Director Nominee
  • Dr. G. Sridhar PrasadIndependent Director Nominee
  • Mr. Myron ShulganIndependent Director Nominee

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company has a clear focus on the pharmaceutical industry for business combinations.
  • Headquartered in Fort Lauderdale, Florida, with a US-based operational presence.
  • Incorporated as an exempted company for business combinations.

Weaknesses

  • Company has only 2 employees, indicating limited operational capacity.
  • Sector and industry classifications are listed as N/A, suggesting lack of defined business focus.
  • IPO date is in the future (2025-01-28), indicating it is not yet operational.

Opportunities

  • Potential to identify and merge with pharmaceutical businesses in the future.
  • Blank check company structure allows flexibility in targeting various business combinations.
  • Focus on pharmaceutical industry could align with growing market trends.

Threats

  • Future IPO date may lead to uncertainty in market positioning.
  • Limited employee count may hinder effective business combination execution.
  • Lack of defined sector and industry may deter potential investors.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.